
26-week randomized
treatment period
iGlarLixi
26-week extension
Continue previous GLP-1 RA
• n = 257 randomized
• n = 256 treated
• n = 246 completed the 26-week
treatment period
R
1:1
+ metformin
± pioglitazone ± SGLT2 inhibitor
iGlarLixi
• n = 257 randomized
• n = 255 treated
• n = 230 completed the 26-week
treatment period
iGlarLixi extension
• n = 206 entered the extension*
• n = 197 completed entire study
Time of primary endpoint measurement